J&J to buy Actelion for US$30b and spin off Swiss drugmaker's R&D unit
World's largest maker of healthcare products pips Sanofi of France to the deal despite walking away earlier
New York
JOHNSON & JOHNSON agreed to buy Actelion Ltd for US$30 billion and spin off the Swiss drugmaker's research and development operations, clinching its largest deal ever to become a leader in medicines treating a rare type of high blood pressure.
With the purchase, J&J, already the world's biggest maker of healthcare products, is fulfilling its goal of adding a new drug category and dealing a blow to France's Sanofi, which had also sought to acquire Actelion.
J&J will begin a tender offer to buy shares of Allschwil, Switzerland-based Actelion for US$280 each in cash, the companies said in a statement.
The price, which equals 280.08 Swiss francs, is 23 per cent above Wednesday's closing level. The R&D operations will be spun off to Acte…
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
France's Casino supermarket chain to axe up to 3,200 jobs
Prada outshines rivals with 16% revenue lift boosted by Miu Miu
Toymaker Hasbro posts quarterly profit beat, slower sales decline
Hilton lifts 2024 profit forecast on international travel demand
China knockoff raid jolts a global throng of fake-fashion influencers
Roche cuts pipeline after research setbacks and sales drop